Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 147 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Background care Clear all
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT02105948
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Mepolizumab, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
837 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
20
States / cities
Newport Beach, California • Rochester, Minnesota • Saint Charles, Missouri + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2018 · Synced Sep 2, 2026, 10:16 PM EDT
Recruiting Phase 3 Interventional

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

NCT05835310
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Anifrolumab, Placebo
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
5 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 2, 2026, 10:16 PM EDT
Recruiting Phase 3 Interventional

A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

NCT06338995
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Interventions
LY3650150, Placebo, Standard therapy for INCS
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 2, 2026, 10:16 PM EDT
Completed Not applicable Interventional

Identifying and Overcoming Barriers to Diabetes Management in the Elderly: An Intervention Study

NCT01480804
View directory record Official record
Conditions
Diabetes
Interventions
Intervention for age specific barriers to self care
Other
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
69 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2014 · Synced Sep 2, 2026, 10:16 PM EDT
Completed No phase listed Observational

Measuring Hope and Hopelessness in Cancer

NCT00581880
View directory record Official record
Conditions
Advanced Cancer
Interventions
questionnaires
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2009 · Synced Sep 2, 2026, 10:16 PM EDT
Recruiting Phase 1 Interventional

A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer

NCT07570979
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Interventions
INR731, Enzalutamide, Abiraterone, Androgen deprivation therapy (ADT)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 2, 2026, 10:16 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Dose of Vestibular Rehabilitation for Vestibular Hypofunction

NCT04851184
View directory record Official record
Conditions
Vestibular Disorder
Interventions
Gaze stabilization Exercises using Virtual Reality Device, Gaze stabilization non-instrumented
Device · Behavioral
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 74 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 2, 2026, 10:16 PM EDT
Completed Not applicable Interventional

At-risk Intervention and Mentoring Evaluation

NCT02174224
View directory record Official record
Conditions
Violence
Interventions
Brief Intervention, Case Management, Standard Medical Care
Behavioral
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
14 Years to 24 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Sep 2, 2026, 10:16 PM EDT
Recruiting Not applicable Interventional

ConsideRAte Study - Splenic Stimulation for RA

NCT05003310
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Active Stimulation, Sham Stimulation, Baricitinib, Background Treatment
Device · Drug
Lead sponsor
Galvani Bioelectronics
Industry
Eligibility
22 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
12
States / cities
Anniston, Alabama • Covina, California • Whittier, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Sep 2, 2026, 10:16 PM EDT
Completed Not applicable Interventional Results available

Monitoring Neonatal Resuscitation Trial

NCT03256578
View directory record Official record
Conditions
Resuscitation, Neonatal Prematurity, Positive-Pressure Respiration
Interventions
New Life Box Respiratory Function Monitor
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
24 Weeks to 28 Weeks
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 21, 2021 · Synced Sep 2, 2026, 10:16 PM EDT
Withdrawn Phase 2 Interventional

Baricitinib for Cutaneous Dermatomyositis

NCT05361109
View directory record Official record
Conditions
Dermatomyositis
Interventions
Baricitinib
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Sep 2, 2026, 10:16 PM EDT
Terminated Phase 2 Interventional Results available

Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

NCT05097989
View directory record Official record
Conditions
Lupus Nephritis, Immunoglobulin A Nephropathy, IgAN, LN
Interventions
ALXN2050, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Huntsville, Alabama • Loma Linda, California • Northridge, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Sep 2, 2026, 10:16 PM EDT
Recruiting Phase 3 Interventional

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

NCT07438496
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Nipocalimab, Placebo, Standard of care treatment
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
36
States / cities
Beverly Hills, California • Fullerton, California • Hemet, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 2, 2026, 10:16 PM EDT
Completed Phase 2 Interventional

MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)

NCT05007106
View directory record Official record
Conditions
Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck, Gallbladder Neoplasms, Cholangiocarcinoma, Esophageal Neoplasms, Triple Negative Breast Neoplasms, Hepatocellular Carcinoma, Urinary Bladder Neoplasms, Ovarian Neoplasms, Stomach Neoplasms
Interventions
Pembrolizumab/Vibostolimab Co-Formulation, Pembrolizumab, Lenvatinib, 5-Fluorouracil, Cisplatin, Paclitaxel, Gemcitabine, Carboplatin, Docetaxel, Bevacizumab, Capecitabine, Oxaliplatin
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
14
States / cities
Anchorage, Alaska • Duarte, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Sep 2, 2026, 10:16 PM EDT
Terminated Phase 2 Interventional Results available

Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

NCT04564339
View directory record Official record
Conditions
Lupus Nephritis, Immunoglobulin A Nephropathy
Interventions
Ravulizumab, Placebo, Background Therapy
Drug · Other
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
17
States / cities
San Dimas, California • Santa Monica, California • South Gate, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 2, 2026, 10:16 PM EDT
Completed No phase listed Observational

Quality of Life, Employment, and Informal Care Costs in Women Who Are Receiving Chemotherapy for Breast Cancer

NCT00115505
View directory record Official record
Conditions
Breast Carcinoma
Interventions
quality-of-life assessment, Questionnaire Administration
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
227
States / cities
Mobile, Alabama • Fort Smith, Arkansas • Fresno, California + 154 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Sep 2, 2026, 10:16 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Maximizing HPV Vaccination: Real-time Reminders, Guidance, and Recommendations - Part 4: Feasibility Trial

NCT03429413
View directory record Official record
Conditions
Human Papillomavirus (HPV) Vaccines
Interventions
Protect Me 4 Application + External Quality Improvement Support, Protect Me 4 Application Alone
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
1,296 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 16, 2025 · Synced Sep 2, 2026, 10:16 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care

NCT03371251
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
BOS161721, Placebo
Drug
Lead sponsor
Boston Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
17
States / cities
Anniston, Alabama • El Cajon, California • Los Alamitos, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2022 · Synced Sep 2, 2026, 10:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Environmental Design for Behavioral Regulation in People With Dementia

NCT04555616
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Standard Environmental Design, Individual Environmental Design, Placebo
Behavioral
Lead sponsor
Elizabeth K Rhodus
Other
Eligibility
21 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Sep 2, 2026, 10:16 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

NCT07169851
View directory record Official record
Conditions
Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms
Interventions
LY3537021, Placebo, Standard of Care Antiemetic Therapies, Background Chemotherapy
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
21
States / cities
Greenbrae, California • Irvine, California • Los Alamitos, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 2, 2026, 10:16 PM EDT
Recruiting Not applicable Interventional

A Pilot Study of Genetic Testing Uptake Through Enhanced Oncology Nurse-Led Intervention

NCT06436157
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
Enhanced education, Usual care education
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Chico, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Sep 2, 2026, 10:16 PM EDT
Completed Not applicable Interventional Results available

Improving Patient Satisfaction Improving Patient Satisfaction

NCT01263639
View directory record Official record
Conditions
Satisfaction, Trauma
Interventions
Orthopaedic Attending Biosketch Card, Standard of care - No biosketch card
Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 27, 2014 · Synced Sep 2, 2026, 10:16 PM EDT
Completed Phase 2 Interventional Results available

Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy

NCT01649765
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Belimumab 10 mg/kg, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 17 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
7
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Augusta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 2, 2026, 10:16 PM EDT
Active, not recruiting Phase 3 Interventional

Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer

NCT02446405
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Enzalutamide, NSAA, LHRHA or Surgical Castration
Drug
Lead sponsor
University of Sydney
Other
Eligibility
18 Years and older · Male only
Enrollment
1,125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Sep 2, 2026, 10:16 PM EDT